Comparative efficacy and safety of antiemetics for pediatric gastroenteritis-related vomiting in emergency departments: a network meta-analysis
Abstract
BACKGROUND: Vomiting is a leading cause of emergency department (ED) visits among children with acute gastroenteritis (AGE). Although antiemetics are commonly used, uncertainty persists regarding the comparative efficacy and safety of individual agents across clinically relevant timeframes.
OBJECTIVE: To compare the efficacy and safety of commonly used antiemetics for pediatric AGE-related vomiting in ED settings using a network meta-analysis (NMA) of randomized controlled trials (RCTs).
METHODS: A systematic search of major databases was conducted through 2025. Eligible studies were RCTs enrolling children ≤21 years presenting to the ED with AGE. Interventions included ondansetron (all routes), dimenhydrinate, domperidone, metoclopramide, bromopride, and placebo. Outcomes included vomiting frequency (short-, intermediate-, and long-term), cessation of vomiting, need for intravenous (IV) rehydration, ED length of stay, hospitalization, and adverse events. A random-effects frequentist NMA was performed. Risk of bias was assessed using ROB-2, and certainty of evidence was evaluated with GRADE.
RESULTS: Thirty-three RCTs were included. In the short term, all ondansetron formulations reduced vomiting compared with placebo, with the strongest effect seen with IV administration (MD -1.86, 95% CI -3.25 to -0.47). For intermediate-term outcomes, IV ondansetron was the only agent consistently superior to placebo and active comparators. For long-term vomiting, dimenhydrinate (oral and…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.